Between 75 and 90% of all clinical samples of neuroblastoma are considered positive for SSTR2 expression [9], and multiple early phase clinical trials have already shown promising results [10] using [177Lu]Lu-DOTATATE for treatment of neuroblastoma. The gene discussed is SSTR2; the disease is neuroblastoma.